Skip to main content
OpenTrials
Completed

NCT Number: NCT06150001

Reduction of Rocuronium-induced Injection Pain With Aspiration of Blood

The goal of this clinical trial is to learn about reduction of rocuronium injection pain in participants receiving general anesthesia. The main question aims to answer is whether diluting rocuronium with blood can reduce rocuronium injection pain. Rocuronium is a rapid onset muscle relaxant used in general anesthesia. Lidocaine is a local anesthetic. Researchers will

• inject diluted rocuronium in participant's intravenous catheter during induction. • record withdrawal movement and rocuronium onset time and duration measured by train-of-four (TOF).

Researchers will compare between rocuronium diluted with blood, lidocaine and normal saline to see if blood can reduce rocuronium injection pain.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anesthesia, General

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

ChangGung MH

Taoyuan, 33380, Taiwan

About this study

This clinical trial uses a random table for sequential randomization, randomly assigning subjects to 3 groups, each consisting of 40 participants.

Researcher will confirm the patency of peripheral intravenous lines before induction. If peripheral intravenous lines cannot be used, they will be readministered at another injection site. If there are difficulties in peripheral intravenous injection, the participant will need to withdraw from this clinical trial. The neuromuscular monitoring device (NMT) is installed before the start of the clinical trial to monitor the effects of the drug. To avoid influencing the final results, fentanyl and 2%lidocaine will not be administered before injecting rocuronium. Anesthesia induction begins with the administration of oxygen through a mask to assist breathing. Initially, propofol is injected at a dose of 1.5 to 2mg/kg. Once the participant is confirmed to have lost consciousness, researchers will inject diluted rocuronium immediately, with an injection speed of 10 to 15 seconds. The dose of rocuronium for each participant is 0.8 mg/kg. The first group is pre-diluted with 2mL of normal saline, the second group with 2mL of 2%lidocaine, and the third group with 2mL of the participant's blood. To avoid clotting of blood, the procedure of the third group involves using a syringe containing rocuronium to withdraw 2mL of blood from the vein, followed by simultaneous injection into the intravenous line. The NMT is used to monitor the drug's effects, defining the onset time as the time from rocuronium injection to the disappearance of train-of-four (TOF) count T1 and the duration of action as the time from rocuronium injection to the appearance of TOF count T1.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing to sign the written informed consent form.
  • Males and females aged 18 to 65.
  • Undergoing endotracheal intubation under general anesthesia.
  • Anesthesia physical status classification II or below.

Exclusion criteria

  • estimated glomerular filtration rate less than 60
  • History of cirrhosis or liver failure
  • Neuromuscular disease or neurological symptoms
  • Mental illness
  • Arrhythmia

Treatment and study plan

rocuronium-normal-saline mixture

Drug

rocuronium will be pre-diluted with 2mL of normal saline. Researchers will inject the mixture into intravenous catheter.

Other names: rocuronium

rocuronium-lidocaine mixture

Drug

rocuronium will be pre-diluted with 2mL of 2%lidocaine. Researchers will inject the mixture into intravenous catheter.

Other names: rocuronium

rocuronium-blood mixture

Drug

Researchers will connect a syringe which contains 0.8mg/kg of rocuronium intravenous catheter, and then withdraw blood into the syringe. Finally inject the mixture into intravenous catheter.

Other names: rocuronium

Primary outcomes

  1. withdrawal movement by 4-point-scale

    Time frame: From enrollment to the end of assessment at thirty minutes.

    withdrawal movement is measured by 4-point-scale. Zero is equivalent to no withdrawal movement. One is equivalent to withdrawal movement involving wrist joint. Two is equivalent to withdrawal movement involving elbow joint. Three is equivalent to withdrawal movement involving shoulder joint

Secondary outcomes

  1. onset time

    Time frame: From enrollment to the end of assessment at 3 minutes.

    onset time is defined by injection of rocuronium mixture to the disappearance of Train-of-four count T1.

  2. duration of action

    Time frame: From enrollment to the end of assessment at one hour.

    Duration of action is defined by injection of rocuronium mixture to appearance of Train-of-four count T1.

Sponsors and collaborators

Lead sponsor

Chang Gung Memorial Hospital

Other

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Nov 29, 2023
Registry last updated
Aug 22, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.